GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FluoGuide AS (OSTO:FLUO) » Definitions » Total Liabilities

FluoGuide AS (OSTO:FLUO) Total Liabilities : kr8.20 Mil (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is FluoGuide AS Total Liabilities?

FluoGuide AS's Total Liabilities for the quarter that ended in Dec. 2024 was kr8.20 Mil.

FluoGuide AS's quarterly Total Liabilities declined from Jun. 2024 (kr5.80 Mil) to Sep. 2024 (kr5.06 Mil) but then increased from Sep. 2024 (kr5.06 Mil) to Dec. 2024 (kr8.20 Mil).

FluoGuide AS's annual Total Liabilities increased from Dec. 2022 (kr5.40 Mil) to Dec. 2023 (kr25.35 Mil) but then declined from Dec. 2023 (kr25.35 Mil) to Dec. 2024 (kr8.20 Mil).


FluoGuide AS Total Liabilities Historical Data

The historical data trend for FluoGuide AS's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FluoGuide AS Total Liabilities Chart

FluoGuide AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial 16.86 20.18 5.40 25.35 8.20

FluoGuide AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.35 22.36 5.80 5.06 8.20

FluoGuide AS Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

FluoGuide AS's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.585+(0.609+0.0010000000000003
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=8.20

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=43.773-35.578
=8.20

FluoGuide AS's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.585+(0.609+0.0010000000000003
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=8.20

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=43.773-35.578
=8.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


FluoGuide AS Total Liabilities Related Terms

Thank you for viewing the detailed overview of FluoGuide AS's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


FluoGuide AS Business Description

Traded in Other Exchanges
Address
Titanhus, Titangade 9-13, Copenhagen, DNK, DK-2200
FluoGuide AS is a clinical-stage biotechnology company focused on developing drugs that maximize surgical outcomes by making cancer fluorescent. Its technology includes uPAR, which is part of a proteolytic system, and FG001, a product injected into the patient's vein prior to surgery.

FluoGuide AS Headlines

No Headlines